TITLE

FDA Faces Challenges Meeting Its Growing Medical Product Responsibilities and Should Develop Complete Estimates of Its Resource Needs

PUB. DATE
July 2009
SOURCE
GAO Reports;7/20/2009, preceding p1
SOURCE TYPE
Government Documents
DOC. TYPE
Article
ABSTRACT
The article reports on the results of an evaluation conducted by the U.S. Government Accountability Office (GAO) on the ability of the Food and Drug Administration (FDA) in meeting its oversight responsibilities on the safety and efficacy of medical products. GAO examined data on the FDA's fiscal year 2004-2008 resources and workload in four key areas. It recommends that the Commissioner of the FDA establish a comprehensive and reliable basis for substantiating the agency's resource needs.
ACCESSION #
43465526

 

Related Articles

  • FDA Needs to Enhance Its Oversight of Drugs Approved on the Basis of Surrogate Endpoints. Crosse, Marcia // GAO Reports;10/26/2009, preceding p1 

    The article focuses on a study by the U.S. Government Accountability Office (GAO) on approved drug applications based on surrogate endpoints under Food and Drug Administration's (FDA) accelerated and traditional approval process and the FDA's oversight of postmarketing studies. FDA is...

  • Opportunities Exist to Better Address Management Challenge. Shames, Lisa; Crosse, Marcia // GAO Reports;3/23/2010, preceding p1 

    The article discusses the review conducted by the Government Accountability Office (GAO) on the strategic planning and management of the Food and Drug Administration (FDA) in the U.S. It states that the GAO studied the Strategic Action Plan of the FDA which comprises strategies in addressing its...

  • Auditors criticise FDA for failing to track workload and costs. Tanne, Janice Hopkins // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;8/1/2009, Vol. 339 Issue 7715, p260 

    The article focuses on a report issued by the U.S. Government Accountability Office regarding the failure of the Food and Drug Administration (FDA) to track its workload. The report, which was issued in January 2009, argued that the failure of FDA to track its workload led to its inability to...

  • FDA Update.  // Pharmaceutical Representative;May2010, Vol. 40 Issue 5, p11 

    The article focuses on a report issued by the U.S. Government Accountability Office (GAO) concerning the strategic planning and management of the Food and Drug Administration (FDA).

  • WEEK IN WASHINGTON.  // BioWorld Insight;2/18/2014, Vol. 22 Issue 7, p6 

    The article offers information on the role of the U.S. Food and Drug Administration for missing out the opportunities to mitigate and proactively prevent drug shortages in the U.S., according to the reports of the U.S. Government Accountability Office (GAO).

  • FDA safety effort necessary.  // Medical Marketing & Media;Feb2010, Vol. 45 Issue 2, p10 

    The article reports on the U.S. Government Accountability Office (GAO) study on the need for the Food and Drug Administration (FDA) to develop a comprehensive plan to prepare the Office of Surveillance and Epidemiology (OSE) to take over additional regulatory authorities from the Office of New...

  • FDA Questioned by Other Feds on High-Risk Devices. Reed, Vita // Orange County Business Journal;4/25/2011, Vol. 34 Issue 17, p65 

    The article reports that the approval of U.S. Food and Drug Administration (FDA) to certain high-risk medical devices such as pacemakers and hip joints, has been criticized by the Government Accountability Office (GAO), which states that the high-risk devices are approved without sufficient...

  • Action Needed to Improve Timeliness and Enhance Scope of FDA's Debarment and Disqualification Processes for Medical Product Investigators. Crosse, Marcia // GAO Reports;10/22/2009, preceding p1 

    The article reports on the study conducted by the U.S. Government Accountability Office (GAO) on the action needed to improve the Food and Drug Administration's (FDA) timely completion of debarment and disqualification processes clinical investigators. It states that investigators who have...

  • FDA panel OKs expanded use for CRT-D.  // Cardiology Today;Jan2012, Vol. 15 Issue 1, p31 

    The article reports on the approval given by a U.S. Food and Drug Administration (FDA) panel to expand the use of Medtronic's cardiac resynchronization therapy defibrillator.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics